Form 4: UTHR President & COO Earns Performance-Based Equity

United Therapeutics' President and COO, Michael Benkowitz, has earned significant performance-based stock options and restricted stock units following the achievement of multi-year targets.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), has earned 99,720 performance-based stock options.
• These stock options have an exercise price of $217.50 per share and will vest on March 15, 2026, with an expiration date of March 15, 2033.
• The options were earned based on a three-year performance condition tied to the average cash profit margin during 2023-2025, which was determined on February 25, 2026.
• Benkowitz also earned 15,592 performance-based restricted stock units (RSUs) tied to average revenue growth during 2023-2025.
• An additional 17,790 performance-based RSUs were earned based on clinical development performance during 2023-2025.
• Both sets of RSUs represent the right to receive one share of common stock each and will vest on March 15, 2026.
• The performance conditions for the revenue growth RSUs were determined on February 25, 2026, and for the clinical development RSUs on January 20, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator, as the successful achievement of performance targets for executive compensation suggests strong underlying company performance in key operational and financial areas over the past three years.

Positives

• The earning of performance-based stock options and restricted stock units indicates that United Therapeutics successfully met its multi-year performance targets related to cash profit margin, revenue growth, and clinical development for the 2023-2025 period.
• The achievement of these targets reflects strong operational and strategic execution by the company's management.

Future Outlook

The earned equity awards are scheduled to vest on March 15, 2026, aligning executive incentives with long-term shareholder value creation.

Industry Context

StockSavvy.ai notes that performance-based equity awards are a common practice in the biotechnology and pharmaceutical industries, designed to align executive compensation with company performance and shareholder interests. The achievement of these targets suggests strong operational execution within a competitive landscape.

Comparison to Industry Standards

• Performance-based compensation, such as the stock options and RSUs awarded to Michael Benkowitz, is a standard practice across the pharmaceutical and biotech sectors, including companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• The three-year performance period (2023-2025) for metrics like cash profit margin, revenue growth, and clinical development is consistent with long-term incentive plans designed to reward sustained performance.
• The vesting schedule on March 15, 2026, for these awards is typical for such long-term incentives, ensuring continued executive commitment post-performance period.

Stakeholder Impact

• Shareholders: The achievement of performance targets for executive compensation suggests strong company performance, which is generally positive for shareholder value.
• Employees: Successful company performance and executive incentives can contribute to a positive corporate culture and potentially future opportunities.

Next Steps

• The earned stock options and restricted stock units will vest on March 15, 2026.

Key Dates

Keywords

UTHR, United Therapeutics, Form 4, insider transaction, stock options, restricted stock units, executive compensation, Michael Benkowitz, performance-based awards